ReviewLife (Basel, Switzerland)2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis (MASLD/MASH) and Cardiovascular Risk: Emerging Therapeutic Strategies at the Interface of Liver and Cardiometabolic Disease.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are increasingly recognized as systemic cardiometabolic disorders rather than isolated liver diseases. Cardiovascular disease (CVD) represents the leading cause of mortality in patients with MASLD/MASH, highlighting the need for therapeutic strategies that address both hepatic and cardiovascular risk. MASLD/MASH and CVD are connected through a network of interdependent mechanisms, including adipose tissue dysfunction, insulin resistance, altered insulin-glucagon signaling, atherogenic dyslipidemia, lipotoxicity, mitochondrial and endoplasmic reticulum stress, innate immune activation, chronic inflammation, endothelial dysfunction, thrombogenic signaling, and dysregulated hepatokine and adipokine pathways. These mechanisms provide potential therapeutic entry points across the liver-adipose tissue-vascular axis. Lifestyle modification and conventional cardiometabolic therapies remain foundational, while several pharmacological agents increasingly target specific components of this network. We summarize the mechanistic rationale and clinical evidence for emerging therapies, including glucagon-like peptide-1 receptor agonists, dual incretin agonists, fibroblast growth factor 21 analogs, thyroid hormone receptor-β agonists, peroxisome proliferator-activated receptor agonists, and agents targeting de novo lipogenesis. We further discuss why residual metabolic, inflammatory, and fibrogenic activity may limit monotherapy and how mechanism-based combination therapy could improve efficacy while mitigating treatment-related metabolic liabilities. Finally, we outline future priorities, including biomarker-guided patient selection, longitudinal noninvasive monitoring, integrated hepatic-cardiovascular trial endpoints, adaptive combination strategies, and development of therapies targeting immune, fibrogenic, and inter-organ signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.